These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1817336)

  • 21. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
    Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
    Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.
    Eschbach JW; Kelly MR; Haley NR; Abels RI; Adamson JW
    N Engl J Med; 1989 Jul; 321(3):158-63. PubMed ID: 2747747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of anemia in hemodialyzed children using recombinant human erythropoietin (Eprex). Results of a French multicenter clinical trial].
    Gagnadoux MF; Loirat C; Berthélémé JP; Maisin A; Kamoun A; Dabout D; Poisson D; Broyer M
    Nephrologie; 1994; 15(3):207-11. PubMed ID: 7969713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of erythropoietin on the dialysis prescription.
    Van Wyck DB
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Erythropoietin--the first hematologic hormone in clinical use].
    Rhyner K
    Schweiz Med Wochenschr; 1988 Mar; 118(11):375-80. PubMed ID: 3287601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
    Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
    Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
    Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
    N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dialysis dose, membrane type, and anemia control.
    Young EW
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S157-60. PubMed ID: 9892384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human erythropoietin: implications for nephrology.
    Eschbach JW; Adamson JW
    Am J Kidney Dis; 1988 Mar; 11(3):203-9. PubMed ID: 3278599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of erythropoietin in predialysis patients.
    Anderson S
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):103-6. PubMed ID: 2024665
    [No Abstract]   [Full Text] [Related]  

  • 31. [Use of human recombinant erythropoietin (rHuEPO) for treatment of anemia in patients with chronic kidney failure who don't require additional dialysis therapy].
    Wiecek A
    Przegl Lek; 1995; 52(3):93-4. PubMed ID: 7644683
    [No Abstract]   [Full Text] [Related]  

  • 32. [Erythropoietin: the significance in therapeutic system of renal failure; clinical efficacy of erythropoietin].
    Nihon Jinzo Gakkai Shi; 1989 May; 31(5):435-9. PubMed ID: 2622074
    [No Abstract]   [Full Text] [Related]  

  • 33. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of anemia in patients on a regular dialysis program using human recombinant erythropoietin].
    Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartůnková J; Válek A
    Cas Lek Cesk; 1989 Sep; 128(40):1257-60. PubMed ID: 2582471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythropoietin for anemia of renal failure in sickle cell disease.
    Steinberg MH
    N Engl J Med; 1991 May; 324(19):1369-70. PubMed ID: 1759999
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical studies of recombinant human erythropoietin in patients on long-term dialysis].
    Ji SM; Li LS; Ji DX
    Zhonghua Nei Ke Za Zhi; 1993 Feb; 32(2):100-2. PubMed ID: 8404323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical efficacy of higher hematocrit levels in children with chronic renal insufficiency and those undergoing dialysis.
    Yorgin PD; Belson A; Al-Uzri AY; Alexander SR
    Semin Nephrol; 2001 Sep; 21(5):451-62. PubMed ID: 11559886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urea kinetics in patients on regular dialysis treatment before and after treatment with recombinant human erythropoietin.
    Zehnter E; Pollok M; Ziegenhagen D; Bramsiepe P; Longere F; Baldamus CA; Wellner U; Waters W
    Contrib Nephrol; 1988; 66():149-55. PubMed ID: 3391029
    [No Abstract]   [Full Text] [Related]  

  • 39. Hematocrit above 30% in continuous ambulatory peritoneal dialysis patients treated with erythropoietin is harmful.
    Junor BJ
    Perit Dial Int; 1993; 13 Suppl 2():S535-7. PubMed ID: 8399658
    [No Abstract]   [Full Text] [Related]  

  • 40. Different answer to recombinant human erythropoietin in anephric and non-anephric haemodialyzed patients.
    Buemi M; Allegra A; Aloisi C; Giacobbe MS; Frisina N
    Nephron; 1990; 56(2):218-9. PubMed ID: 2243581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.